There was no association between tumor response and the arterial enhancement on pre-TACE CT, the occurrence of tumor lipiodol enhancement during TACE, the total dose of doxorubicin, tumor size (>8 cm in 12/73 patients), type of cirrhosis, serum levels of albumin, CRP, and AFP before the first treatment. The gene discussed is CRP; the disease is neoplasm.